THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTATION OF STANDARDIZED SEROLOGY TESTING FOR ITS INTE
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N91019D00024-P00025-759102000003-60
Grant search
Key facts
Disease
COVID-19Start & end year
20202023Known Financial Commitments (USD)
$579,629Funder
National Institutes of Health (NIH)Principal Investigator
LEONARD FREEDMANResearch Location
United States of AmericaLead Research Institution
LEIDOS BIOMEDICAL RESEARCH, INC.Research Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
The following support shall be provided for Therapeutic Development Branch: • Continuation of the "Integrated Data Resource for Rare Diseases" working with Advanced Biomedical Computational Science at Leidos Biomedical Research, Inc.; • Assay validation and non-GMP and GMP manufacturing of batches of drug substance and drug product; • Stability studies to support projects with GMP and / or non-GMP products; • Biodistribution / imaging and pharmacokinetic studies; • Consulting services for development of bioanalytical methods; • Regulatory services to support preclinical and / or clinical-stage projects; • Electron microscopy studies; • Gene expression and proteomic data analyses and cell-based screening studies; • Proteomic profiling, cell-based efficacy studies, and clinical trials for canine comparative oncology; • Laboratory animal support.